NantKwest

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics

Denali Therapeutics

Seres Therapeutics

Rocket Pharma

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

5 Medical Outperformers That Might Lose Steam in 2021

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated ImmunityBio, Inc. (“ImmunityBio”) and NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company. CytRx out-licensed global development, manufacturing and commerciali

CytRx Comments on Proposed Combination of ImmunityBio and NantKwest

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) in connection with the Company's proposed merger with ImmunityBio,...

SHAREHOLDER ALERT: WeissLaw LLP Investigates NantKwest, Inc.

A merger agreement with a fellow immunotherapy company is exciting investors today.

Why NantKwest Is Jumping Today

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. Together, ImmunityBio and NantKwest will have a broad, clinical-stage p

ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will participate in institutional investor meetings on Tuesday, December 1; meetings may be requested through Piper Sandler. Additiona

NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no serious adverse events (SAE) reported in the low dose cohort, safety is ongoing for the high dose cohort. The trial, being conducted at

ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational skills Richard Adcock as its Chief Executive Officer, effective immediately. Adcock brings extensive leadership experience to NantKwest as the company advances rapidly in the development of natural killer cell-based immunotherapies for cancer and serious infectious diseases. Rich will assume the r

NantKwest Names Richard Adcock Chief Executive Officer

NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300.

NantKwest COVID-19 Candidate, And Other News: The Good, Bad And Ugly Of Biopharma

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that the first patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (S

ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced they have added a third cohort to their ongoing Phase 2 trial of a novel immunotherapy for locally advanced or metastatic pancreatic cancer. The third cohort enables pancreatic cancer patients who have failed all approved standards of care to participate in the trial. Th

NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available on the NantKwest website, NantKwest.com. An archived replay will be available on the website for approximately 30 days. About NantKwest NantKwest (NASDA

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

SAN DIEGO--(BUSINESS WIRE)--Brink Biologics, Inc. (“Brink”), a NantKwest, Inc.

Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, today announced a collaboration to develop.

Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment

NantKwest (NK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NantKwest (NK) to Report a Decline in Earnings: What to Look Out for

Altimmune

Dynavax Technologies

Novavax

VBI Vaccines

My COVID-19 Vaccine Report Card

NantKwest: The Market And The Government Are Missing Out On This Blockbuster

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong), which inc

NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong). The aggregate gross proceeds fr

NantKwest Announces Pricing of Public Offering of Common Stock

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, NantKwest expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. NantKwest intends to use the net proceeds of the

NantKwest Announces Proposed Public Offering of Common Stock

Investors are excited about the biotech's COVID-19 vaccine targeting a different part of the novel coronavirus.

Here's Why NantKwest Rocketed Higher Today

Nantkwest Inc (NASDAQ: NK) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options.

NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates

Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to Monday's gains in Tuesday's session.

NantKwest In 'Active Discussions' With FDA On COVID-19 Vaccine, Therapeutic Development

Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.

News for NantKwest Stock (NK)